21. A process to prepare pharmaceutical tablets containing paroxetine, on a commercial scale, which process comprises the steps of:

a) dry admixing paroxetine and dry excipients in a mixer to form a mixture; or

b) dry admixing paroxetine and dry excipients, compressing the resulting combination into a slug material or roller compacting the resulting combination into a strand material, and milling the prepared material into a free flowing mixture; and

c) compressing the mixture into tablets,

provided that the excipients include at least one of: sodium starch glycollate, dicalcium phosphate and magnesium stearate;

and further provided that one of the excipients that is compressed into tablets is not microcrystalline cellulose.

22. A process according to claim 20 in which the amount of paroxetine in each tablet is selected from: 10 mg, 20 mg, 30 mg, 40 mg and 50 mg, wherein the amount of paroxetine is expressed as the free base.

23. A process according to claim 21 in which the amount of paroxetine in each tablet is selected from: 10 mg, 20 mg, 30 mg, 40 mg and 50 mg, wherein the amount of paroxetine is expressed as the free base.

24. A process according to claim 22 in which the amount of paroxetine in each tablet is about 10 mg, wherein the amount of paroxetine is expressed as the free base.

25. A process according to claim 23 in which the amount of paroxetine in each tablet is about 10 mg, wherein the amount of paroxetine is expressed as the free base.

26. A process according to claim 22 in which the amount of paroxetine in each tablet is about 20 mg, wherein the amount of paroxetine is expressed as the free base.

27. A process according to claim 23 in which the amount of paroxetine in each tablet is about 20 mg, wherein the amount of paroxetine is expressed as the free base.

28. A process according to claim 22 in which the amount of paroxetine in each tablet is about 30 mg, wherein the amount of paroxetine is expressed as the free base.

29. A process according to claim 23 in which the amount of paroxetine in each tablet is about 30 mg, wherein the amount of paroxetine is expressed as the free base.

30. A process according to claim 22 in which the amount of paroxetine in each tablet is about 40 mg, wherein the amount of paroxetine is expressed as the free base.

31. A process according to claim 23 in which the amount of paroxetine in each tablet is about 40 mg, wherein the amount of paroxetine is expressed as the free base.

32. A process according to claim 22 in which the amount of paroxetine in each tablet is about 50 mg, wherein the amount of paroxetine is expressed as the free base.

33. A process according to claim 23 in which the amount of paroxetine in each tablet is about 50 mg, wherein the amount of paroxetine is expressed as the free base.

REMARKS

Applicants wish to thank the Examiner for the courtesy extended the undersigned attorney during the interview which took place on October 3, 2002 in the above noted parent application and the subsequent telephonic conversation which took place on or about October 31, 2002. In view of these conversations, favorable consideration of the process claims as presented herein is respectfully requested. Applicants also wish to thank the Examiner for the courtesy extended the undersigned attorney during a telephone conversation which took place on July 7, 2003, in which it was noted that the filing of an RCE in the instant application was a desirable means of presenting the above process claims to the Examiner in an expeditious manner.